The FDA has issued a complete response letter for Cingulate’s new drug application seeking approval of CTx-1301 for the treatment of attention-deficit/hyperactivity disorder.
The agency’s response identified specific Chemistry, Manufacturing and Controls information requests and did not raise any current concerns regarding the clinical safety or efficacy of CTx-1301 (dexmethylphenidate HCl), according to a June 2 news release from the drugmaker.
CTx-1301 takes a familiar molecule — dexmethylphenidate, the active form of a decades-old ADHD stimulant — and rebuilds how it is delivered: one tablet that releases medication three separate times throughout the day, rather than all at once or in a slow, continuous drip.
Cingulate said it expects to promptly submit the requested information to address the issues raised by the FDA.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.